(12) Patent Application Publication (10) Pub. No.: US 2017/0143734 A1 DE COLLE Et Al
US 20170143734A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0143734 A1 DE COLLE et al. (43) Pub. Date: May 25, 2017 (54) PRODRUGS OF METOPMAZINE Publication Classification (51) Int. Cl. (71) Applicant: Neurogastrx, Inc., Campbell, CA (US) A6II 3/545 (2006.01) A6IR 9/00 (2006.01) (72) Inventors: Cyril DE COLLE, Campbell, CA A 6LX 9/70 (2006.01) (US); Pankaj PASRICHA, Ellicott C07D 417/06 (2006.01) City, MD (US); David WUSTROW, A63L/98 (2006.01) Los Gatos, CA (US) (52) U.S. Cl. (21) Appl. No.: 15/320,724 CPC ........ A6IK3I/5415 (2013.01); C07D 417/06 (2013.01); A61K 31/198 (2013.01); A61 K (22) PCT Fed: Jun. 23, 2015 9/7023 (2013.01); A61K 9/006 (2013.01) (86) PCT No.: PCT/US 15/37258 (57) ABSTRACT S 371 (c)(1), Provided herein are methods, compounds, compositions, and kits for the treatment of an enteric nervous system (2) Date: Dec. 20, 2016 disorder. Such methods may comprise administering to a Subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, Related U.S. Application Data and/or a peripherally restricted dopamine D2 receptor (60) Provisional application No. 62/016.235, filed on Jun. antagonist that does not substantially inhibit hERG chan 24, 2014. nels. Patent Application Publication May 25, 2017. Sheet 1 of 2 US 2017/O143734 A1 Repeated measures one-way ANOVA data 2 5 2 O 1 5 1 O FIGURE 1 Patent Application Publication May 25, 2017. Sheet 2 of 2 US 2017/O143734 A1 Solid Gastric Emptying (%) QCcodoG |- ODCON,COLO<!--(NI<- G2Cco ||||||| IIIIII FIGURE 2 US 2017/O 143734 A1 May 25, 2017 PRODRUGS OF METOPMAZINE The safety concerns relate to (1) unwanted cardiac side effects caused by, e.g., interaction of the agents with ion CROSS-REFERENCE channels involved in cardiac action potentials, and (2) unwanted motor dysfunction caused by the actions of the 0001.
[Show full text]